You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.

Why Lipoprotein (a) Matters Regarding Cardiovascular Risk, and What’s New?

Authors: Eric S. G. Stroes, MD, PhD; Samia Mora, MD, MHS; Børge G. Nordestgaard, MD, DMScFaculty and Disclosures


Posted: 28/11/2022

This educational activity is intended for an international audience of non-US cardiologists, primary care physicians, and nephrologists.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Need to screen for Lp(a)
  • Have greater competence related to
    • Screening for Lp(a)
    • Managing Lp(a)

Educational Impact Challenge

The goal of this activity is for learners to be better able to apply recent updates on Lp(a) in atherosclerotic cardiovascular disease (ASCVD) and particularly on the 2022 European Atherosclerotic Society (EAS) Consensus Statement. 

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print